entertainment -WSS

entertainment

author：comprehensive 2025-10-02 22:24:40 - browse：5811

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Why health care costs have stayed mostly flat since 2010

WSS

Why health care costs have stayed mostly flat since 2010

How to keep neuroscience’s past racism from being its future

Diversity in medical illustrations gets boost from Chidiebere Ibe

Diversity in medical illustrations gets boost from Chidiebere Ibe

Drinking less cuts risk of oral cavity, esophageal cancer: Report

How to make AI work for medicine

focus

entertainment

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Grail spinoff by Illumina should end disastrous merger attempt

Drug repurposing or repositioning? The language matters

Diversity in medical illustrations gets boost from Chidiebere Ibe

How to save PrEP access — and even expand it

Albert Bourla of Pfizer: worst biopharma CEO of 2023

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Neuroscience startup Neumora files for IPO

ChatGPT in medicine: STAT answers readers' burning questions

Feds fine Medicare Advantage plans for overcharging members

explore

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Hospitals owned by private equity see complications spike 25%

How to make Best Hospitals ratings actually useful for patients

FDA panel gives mixed vote on blood pressure devices

Can sheer will power keep patients alive in their dying hours?

Keeping primary care docs in field isn't impossible, says AAFP CEO

hotspot

knowledge

hotspot

hotspot